{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:01:54Z","timestamp":1789639314231,"version":"4.0.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41401-026-01845-2","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:50:54Z","timestamp":1782690654000},"page":"3024-3041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting BCL9\/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1\/STAT4 signaling"],"prefix":"10.1038","volume":"47","author":[{"given":"Yuan-yuan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-si","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-jing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-zhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-fang","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1845_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566\u201376.","journal-title":"Nat Med"},{"key":"1845_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25:454\u201361.","journal-title":"Nat Med"},{"key":"1845_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov. 2021;20:899\u2013919.","journal-title":"Nat Rev Drug Discov"},{"key":"1845_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser DE, Chijioke O, Schaeuble K, M\u00fcnz C. CD4+ T cells in cancer. Nat Cancer. 2023;4:317\u201329.","journal-title":"Nat Cancer"},{"key":"1845_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","volume":"38","author":"M Ruterbusch","year":"2020","unstructured":"Ruterbusch M, Pruner KB, Shehata L, Pepper M. In vivo CD4+ T cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu Rev Immunol. 2020;38:705\u201325.","journal-title":"Annu Rev Immunol"},{"key":"1845_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202200169","volume":"7","author":"B Wang","year":"2023","unstructured":"Wang B, Hu S, Fu X, Li L. CD4+ Cytotoxic T lymphocytes in cancer immunity and immunotherapy. Adv Biol (Weinh). 2023;7:e2200169.","journal-title":"Adv Biol (Weinh)"},{"key":"1845_CR7","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54:2701\u201311.","journal-title":"Immunity"},{"key":"1845_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood.2024025875","volume":"146","author":"S Kim","year":"2025","unstructured":"Kim S, Kwak JE, Koh JY, Lee JE, Kook HW, Kim M, et al. NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma. Blood. 2025;146:456\u201370.","journal-title":"Blood"},{"key":"1845_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3348","volume":"7","author":"A Cachot","year":"2021","unstructured":"Cachot A, Bilous M, Liu YC, Li X, Saillard M, Cenerenti M, et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. 2021;7:eabe3348.","journal-title":"Sci Adv"},{"key":"1845_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11065-0","volume":"23","author":"A Vienot","year":"2023","unstructured":"Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, et al. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82). BMC Cancer. 2023;23:710.","journal-title":"BMC Cancer"},{"key":"1845_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/ijms22020523","volume":"22","author":"J Kervevan","year":"2021","unstructured":"Kervevan J, Chakrabarti LA. Role of CD4+ T cells in the control of viral infections: recent advances and open questions. Int J Mol Sci. 2021;22:523.","journal-title":"Int J Mol Sci"},{"key":"1845_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985\u201399.","journal-title":"Cell"},{"key":"1845_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08586-3","volume":"10","author":"DM Gay","year":"2019","unstructured":"Gay DM, Ridgway RA, M\u00fcller M, Hodder MC, Hedley A, Clark W, et al. Loss of BCL9\/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer. Nat Commun. 2019;10:723.","journal-title":"Nat Commun"},{"key":"1845_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.molcel.2006.09.001","volume":"24","author":"J Sampietro","year":"2006","unstructured":"Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. Crystal structure of a beta-catenin\/BCL9\/Tcf4 complex. Mol Cell. 2006;24:293\u2013300.","journal-title":"Mol Cell"},{"key":"1845_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13842-7","volume":"11","author":"M Jiang","year":"2020","unstructured":"Jiang M, Kang Y, Sewastianik T, Wang J, Tanton H, Alder K, et al. BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins. Nat Commun. 2020;11:19.","journal-title":"Nat Commun"},{"key":"1845_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12072-019-09977-w","volume":"14","author":"N Huge","year":"2020","unstructured":"Huge N, Sandbothe M, Schr\u00f6der AK, Stalke A, Eilers M, Sch\u00e4ffer V, et al. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma. Hepatol Int. 2020;14:373\u201384.","journal-title":"Hepatol Int"},{"key":"1845_CR17","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1038\/s41388-021-02016-9","volume":"40","author":"V Vafaizadeh","year":"2021","unstructured":"Vafaizadeh V, Buechel D, Rubinstein N, Kalathur RKR, Bazzani L, Saxena M, et al. The interactions of Bcl9\/Bcl9L with \u03b2-catenin and Pygopus promote breast cancer growth, invasion, and metastasis. Oncogene. 2021;40:6195\u2013209.","journal-title":"Oncogene"},{"key":"1845_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41392-024-01838-9","volume":"9","author":"F He","year":"2024","unstructured":"He F, Wu Z, Liu C, Zhu Y, Zhou Y, Tian E, et al. Targeting BCL9\/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal Transduct Target Ther. 2024;9:139.","journal-title":"Signal Transduct Target Ther"},{"key":"1845_CR19","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1038\/s41388-021-01756-y","volume":"40","author":"X Wang","year":"2021","unstructured":"Wang X, Feng M, Xiao T, Guo B, Liu D, Liu C, et al. BCL9\/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene. 2021;40:2982\u201397.","journal-title":"Oncogene"},{"key":"1845_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau5240","volume":"5","author":"M Feng","year":"2019","unstructured":"Feng M, Jin JQ, Xia L, Xiao T, Mei S, Wang X, et al. Pharmacological inhibition of \u03b2-catenin\/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Sci Adv. 2019;5:eaau5240.","journal-title":"Sci Adv"},{"key":"1845_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41392-021-00730-0","volume":"6","author":"M Feng","year":"2021","unstructured":"Feng M, Wu Z, Zhou Y, Wei Z, Tian E, Mei S, et al. BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer. Signal Transduct Target Ther. 2021;6:313.","journal-title":"Signal Transduct Target Ther"},{"key":"1845_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115708","volume":"44","author":"F Yang","year":"2025","unstructured":"Yang F, Li A, Zhu Y, Zhou Y, Tian E, Yang M, et al. GATA1-mediated Notch signaling augment antitumor immunity of CD11b+CD27- natural killer cells maturation via BCL9\/\u03b2-catenin signal. Cell Rep. 2025;44:115708.","journal-title":"Cell Rep"},{"key":"1845_CR23","doi-asserted-by":"publisher","first-page":"e1000296","DOI":"10.1371\/journal.pbio.1000296","volume":"8","author":"D Notani","year":"2010","unstructured":"Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S, et al. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol. 2010;8:e1000296.","journal-title":"PLoS Biol"},{"key":"1845_CR24","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/ni.1762","volume":"10","author":"Q Yu","year":"2009","unstructured":"Yu Q, Sharma A, Oh SY, Moon HG, Hossain MZ, Salay TM, et al. T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat Immunol. 2009;10:992\u20139.","journal-title":"Nat Immunol"},{"key":"1845_CR25","doi-asserted-by":"publisher","first-page":"225ra28","DOI":"10.1126\/scitranslmed.3007607","volume":"6","author":"S Keerthivasan","year":"2014","unstructured":"Keerthivasan S, Aghajani K, Dose M, Molinero L, Khan MW, Venkateswaran V, et al. \u03b2-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci Transl Med. 2014;6:225ra28.","journal-title":"Sci Transl Med"},{"key":"1845_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.tips.2018.03.008","volume":"39","author":"B Wang","year":"2018","unstructured":"Wang B, Tian T, Kalland KH, Ke X, Qu Y. Targeting Wnt\/\u03b2-Catenin signaling for cancer immunotherapy. Trends Pharmacol Sci. 2018;39:648\u201358.","journal-title":"Trends Pharmacol Sci"},{"key":"1845_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"IMP Badia","year":"2022","unstructured":"Badia IMP, V\u00e9lez Santiago J, Braunger J, Geiss C, Dimitrov D, M\u00fcller-Dott S, et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform Adv. 2022;2:vbac016.","journal-title":"Bioinform Adv"},{"key":"1845_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","volume":"30","author":"M Ceribelli","year":"2016","unstructured":"Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764\u201378.","journal-title":"Cancer Cell"},{"key":"1845_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4048\/jbc.2021.24.e34","volume":"24","author":"S Banik","year":"2021","unstructured":"Banik S, Rakshit S, Sarkar K. The role of STAT1 in T helper cell differentiation during breast cancer progression. J Breast Cancer. 2021;24:253\u201365.","journal-title":"J Breast Cancer"},{"key":"1845_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114730","volume":"162","author":"DH Jung","year":"2023","unstructured":"Jung DH, Lee A, Hwang YH, Jung MA, Pyun BJ, Lee JY, et al. Therapeutic effects of Pulsatilla koreana Nakai extract on ovalbumin-induced allergic rhinitis by inhibition of Th2 cell activation and differentiation via the IL-4\/STAT6\/GATA3 pathway. Biomed Pharmacother. 2023;162:114730.","journal-title":"Biomed Pharmacother"},{"key":"1845_CR31","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.4049\/jimmunol.1201606","volume":"190","author":"H Suga","year":"2013","unstructured":"Suga H, Sugaya M, Miyagaki T, Ohmatsu H, Okochi H, Sato S. CXCR3 deficiency prolongs Th1-type contact hypersensitivity. J Immunol. 2013;190:6059\u201370.","journal-title":"J Immunol"},{"key":"1845_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"1845_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1349-7006.2007.00646.x","volume":"99","author":"T Shimauchi","year":"2008","unstructured":"Shimauchi T, Kabashima K, Tokura Y. Adult T-cell leukemia\/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Sci. 2008;99:98\u2013106.","journal-title":"Cancer Sci"},{"key":"1845_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1172\/JCI82976","volume":"127","author":"C Berlato","year":"2017","unstructured":"Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, et al. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. J Clin Invest. 2017;127:801\u201313.","journal-title":"J Clin Invest"},{"key":"1845_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204.","journal-title":"Signal Transduct Target Ther"},{"key":"1845_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/ni1104","volume":"5","author":"B Liu","year":"2004","unstructured":"Liu B, Mink S, Wong KA, Stein N, Getman C, Dempsey PW, et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol. 2004;5:891\u20138.","journal-title":"Nat Immunol"},{"key":"1845_CR37","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1126\/science.278.5344.1803","volume":"278","author":"CD Chung","year":"1997","unstructured":"Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278:1803\u20135.","journal-title":"Science"},{"key":"1845_CR38","doi-asserted-by":"publisher","first-page":"10626","DOI":"10.1073\/pnas.95.18.10626","volume":"95","author":"B Liu","year":"1998","unstructured":"Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA. 1998;95:10626\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1845_CR39","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1073\/pnas.051489598","volume":"98","author":"B Liu","year":"2001","unstructured":"Liu B, Gross M, ten Hoeve J, Shuai K. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proc Natl Acad Sci USA. 2001;98:3203\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1845_CR40","doi-asserted-by":"publisher","first-page":"21327","DOI":"10.1074\/jbc.C300119200","volume":"278","author":"T Arora","year":"2003","unstructured":"Arora T, Liu B, He H, Kim J, Murphy TL, Murphy KM, et al. PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4. J Biol Chem. 2003;278:21327\u201330.","journal-title":"J Biol Chem"},{"key":"1845_CR41","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/cmdc.202000839","volume":"16","author":"D Kessler","year":"2021","unstructured":"Kessler D, Mayer M, Zahn SK, Zeeb M, W\u00f6hrle S, Bergner A, et al. Getting a grip on the undrugged: targeting \u03b2-Catenin with fragment-based methods. ChemMedChem. 2021;16:1420\u20134.","journal-title":"ChemMedChem"},{"key":"1845_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-024-08076-7","volume":"636","author":"MA Cardenas","year":"2024","unstructured":"Cardenas MA, Prokhnevska N, Sobierajska E, Gregorova P, Medina CB, Valanparambil RM, et al. Differentiation fate of a stem-like CD4 T cell controls immunity to cancer. Nature. 2024;636:224\u201332.","journal-title":"Nature"},{"key":"1845_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, et al. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours. Nature. 2023;618:1033\u201340.","journal-title":"Nature"},{"key":"1845_CR44","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4+ CAR T-cell antitumor activity. Nat Cancer. 2023;4:968\u201383.","journal-title":"Nat Cancer"},{"key":"1845_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6235614","volume":"2016","author":"W Dai","year":"2016","unstructured":"Dai W, Liu F, Li C, Lu Y, Lu X, Du S, et al. Blockade of Wnt\/\u03b2-Catenin pathway aggravated silica-induced lung inflammation through Tregs regulation on Th immune responses. Mediators Inflamm. 2016;2016:6235614.","journal-title":"Mediators Inflamm"},{"key":"1845_CR46","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1158\/0008-5472.CAN-09-0773","volume":"69","author":"M Mani","year":"2009","unstructured":"Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 2009;69:7577\u201386.","journal-title":"Cancer Res"},{"key":"1845_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-199","volume":"8","author":"M de la Roche","year":"2008","unstructured":"de la Roche M, Worm J, Bienz M. The function of BCL9 in Wnt\/beta-catenin signaling and colorectal cancer cells. BMC Cancer. 2008;8:199.","journal-title":"BMC Cancer"},{"key":"1845_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","volume":"47","author":"M Melssen","year":"2017","unstructured":"Melssen M, Slingluff CL Jr. Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol. 2017;47:85\u201392.","journal-title":"Curr Opin Immunol"},{"key":"1845_CR49","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.4049\/jimmunol.1700247","volume":"199","author":"D Sorcini","year":"2017","unstructured":"Sorcini D, Bruscoli S, Frammartino T, Cimino M, Mazzon E, Galuppo M, et al. Wnt\/\u03b2-catenin signaling induces integrin \u03b14\u03b21 in T cells and promotes a progressive neuroinflammatory disease in mice. J Immunol. 2017;199:3031\u201341.","journal-title":"J Immunol"},{"key":"1845_CR50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/intimm\/dxr029","volume":"23","author":"R Yagi","year":"2011","unstructured":"Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int Immunol. 2011;23:415\u201320.","journal-title":"Int Immunol"},{"key":"1845_CR51","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","volume":"28","author":"JJ O\u2019Shea","year":"2008","unstructured":"O\u2019Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28:477\u201387.","journal-title":"Immunity"},{"key":"1845_CR52","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/cells9102297","volume":"9","author":"A Hoya","year":"2020","unstructured":"Hoya A, Soto-Cruz I. Role of the JAK\/STAT pathway in cervical cancer: its relationship with HPV E6\/E7 oncoproteins. Cells. 2020;9:2297.","journal-title":"Cells"},{"key":"1845_CR53","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.3389\/fimmu.2018.02392","volume":"9","author":"GJ Niu","year":"2018","unstructured":"Niu GJ, Xu JD, Yuan WJ, Sun JJ, Yang MC, He ZH, et al. Protein inhibitor of activated STAT (PIAS) negatively regulates the JAK\/STAT pathway by inhibiting STAT phosphorylation and translocation. Front Immunol. 2018;9:2392.","journal-title":"Front Immunol"},{"key":"1845_CR54","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.4049\/jimmunol.178.7.4284","volume":"178","author":"C Reardon","year":"2007","unstructured":"Reardon C, McKay DM. TGF-\u03b2 Suppresses IFN-\u03b3-STAT1-dependent gene transcription by enhancing STAT1-PIAS1 interactions in epithelia but not monocytes\/macrophages1. J Immunol. 2007;178:4284\u201395.","journal-title":"J Immunol"},{"key":"1845_CR55","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1182\/blood-2011-04-347930","volume":"118","author":"A Begitt","year":"2011","unstructured":"Begitt A, Droescher M, Knobeloch K-P, Vinkemeier U. SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFN\u03b3. Blood. 2011;118:1002\u20137.","journal-title":"Blood"},{"key":"1845_CR56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/emboj.2010.290","volume":"30","author":"DJC Tai","year":"2011","unstructured":"Tai DJC, Hsu WL, Liu YC, Ma YL, Lee EHY. Novel role and mechanism of protein inhibitor of activated STAT1 in spatial learning. EMBO J. 2011;30:205\u201320.","journal-title":"EMBO J"},{"key":"1845_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2021.104216","volume":"125","author":"S Lu","year":"2021","unstructured":"Lu S, Peng X, Zeng S, Deng H, Feng Z, Zeng Q, et al. Grass carp (Ctenopharyngodon idellus) PIAS1 inhibits innate immune response via interacting with STAT1. Dev Comp Immunol. 2021;125:104216.","journal-title":"Dev Comp Immunol"},{"key":"1845_CR58","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","volume":"10","author":"E Montauti","year":"2024","unstructured":"Montauti E, Oh DY, Fong L. CD4+ T cells in antitumor immunity. Trends Cancer. 2024;10:969\u201385.","journal-title":"Trends Cancer"},{"key":"1845_CR59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","volume":"45","author":"M Guo","year":"2024","unstructured":"Guo M, Liu MYR, Brooks DG. Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy. Trends Immunol. 2024;45:303\u201313.","journal-title":"Trends Immunol"},{"key":"1845_CR60","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574:696\u2013701.","journal-title":"Nature"},{"key":"1845_CR61","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fimmu.2017.00194","volume":"8","author":"A Takeuchi","year":"2017","unstructured":"Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function. Front Immunol. 2017;8:194.","journal-title":"Front Immunol"},{"key":"1845_CR62","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","volume":"52","author":"A \u015aledzi\u0144ska","year":"2020","unstructured":"\u015aledzi\u0144ska A, Vila de Mucha M, Bergerhoff K, Hotblack A, Demane DF, Ghorani E, et al. Regulatory T cells restrain interleukin-2- and Blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells. Immunity. 2020;52:151\u201366.e6.","journal-title":"Immunity"},{"key":"1845_CR63","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/ni.2523","volume":"14","author":"D Mucida","year":"2013","unstructured":"Mucida D, Husain MM, Muroi S, van Wijk F, Shinnakasu R, Naoe Y, et al. Transcriptional reprogramming of mature CD4\u207a helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat Immunol. 2013;14:281\u20139.","journal-title":"Nat Immunol"},{"key":"1845_CR64","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, Melief CJM, Kastenm\u00fcller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:635\u201347.","journal-title":"Nat Rev Immunol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01845-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:37Z","timestamp":1789635757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01845-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01845-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}